 VANCOUVER, British Columbia, June 17, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM, a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that its continued optimization of IntegraSynTM has increased the cannabinoid yield to a level of 5 gL, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. 